Login to Your Account

Kael-Gemvax Forging Ahead Despite Cancer Vaccine Failure

By Nuala Moran
STaff Writer

Tuesday, June 18, 2013
LONDON – South Korean biotech Kael-Gemvax is planning further investment and new clinical trials of GV1001, despite the cancer vaccine failing to meet the primary endpoint in a 1,062-patient UK Phase III trial that reported earlier this month.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription